Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBM6-AD + poly-ICLC
- Development stage
- Unknown
- Lead developer
- University of Minnesota
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
GBM6-AD + poly-ICLC is a cancer vaccine combining tumor-cell lysate (GBM6-AD) with poly-ICLC as an immune adjuvant. The GBM6-AD component is derived from the GBM6 cell line, which expresses antigens commonly found in glioma cells. The preparation involves culturing tumor cells, lysing them to release tumor-associated antigens (TAAs), and combining this lysate with poly-ICLC. Poly-ICLC (Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose) acts as a potent immune adjuvant by activating pattern recognition receptors like toll-like receptor 3 (TLR3) on dendritic cells, leading to production of type-1 interferons and cytokines that promote a Th1-type immune response. The vaccine is administered intradermally to effectively deliver it to immune cells in the skin, particularly dendritic cells, which then present the antigens to T cells in the lymph nodes.
- Other names
- GBM6-AD lysate plus poly-ICLCGBM-6-AD lysate plus poly-ICLCGBM 6-AD lysate plus poly-ICLCGBM6-AD lysate and poly-ICLCGBM-6-AD lysate and poly-ICLCGBM 6-AD lysate and poly-ICLCGBM6-AD vaccineGBM-6-AD vaccineGBM 6-AD vaccine
02
Targets
TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on GBM6-AD + poly-ICLC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBM6-AD + poly-ICLC.